Please assess the completion status of the following clinical trial:

Trial Title: Lamictal in the Treatment of Post-Herpetic Neuralgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All patients will be over the age of 18,~* Need to have a diagnosis of Post-Herpetic Neuralgia,~* Minimum of 4 on the Likert Pain Scale,~* If currently taking TCA and/or Gabapentin, need to have been on stable dose for minimum of 4 weeks~Exclusion Criteria:~* Currently on any antiepileptic drugs (AED), except for Gabapentin.~* Currently taking opioid or unwilling to washout prior to the study,~* Pregnant and lactating,~* Have active severe systemic disease,~* History of Stevens-Johnson syndrome or TEN,~* Clinically significant abnormal lab values,~* Known drug allergy to Lamictal,~* Patients on Fibrates (Tricor and Lopid),~* History of major psychiatric disturbance and substance abuse.~* Valproate due to increase chances of severe rash,~* Lidocaine Patch,~* Use of hormonal contraceptives (birth control pills, patch, ring, injection)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).